- Home
- ZEO vs ELEV Comparison
ZEO vs ELEV Comparison
Compare ZEO & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- ELEV
- Stock Information
- Founded
- ZEO 2005
- ELEV 2019
- Country
- ZEO United States
- ELEV United States
- Employees
- ZEO N/A
- ELEV N/A
- Industry
- ZEO
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- ELEV Health Care
- Exchange
- ZEO NYSE
- ELEV Nasdaq
- Market Cap
- ZEO 21.7M
- ELEV 20.0M
- IPO Year
- ZEO N/A
- ELEV 2021
- Fundamental
- Price
- ZEO $1.58
- ELEV $0.34
- Analyst Decision
- ZEO
- ELEV Buy
- Analyst Count
- ZEO 0
- ELEV 6
- Target Price
- ZEO N/A
- ELEV $2.94
- AVG Volume (30 Days)
- ZEO 1.2M
- ELEV 975.2K
- Earning Date
- ZEO 05-20-2025
- ELEV 05-23-2025
- Dividend Yield
- ZEO N/A
- ELEV N/A
- EPS Growth
- ZEO N/A
- ELEV N/A
- EPS
- ZEO N/A
- ELEV N/A
- Revenue
- ZEO $77,582,314.00
- ELEV N/A
- Revenue This Year
- ZEO N/A
- ELEV N/A
- Revenue Next Year
- ZEO N/A
- ELEV N/A
- P/E Ratio
- ZEO N/A
- ELEV N/A
- Revenue Growth
- ZEO N/A
- ELEV N/A
- 52 Week Low
- ZEO $1.05
- ELEV $0.22
- 52 Week High
- ZEO $5.05
- ELEV $4.33
- Technical
- Relative Strength Index (RSI)
- ZEO 47.40
- ELEV 48.18
- Support Level
- ZEO $1.54
- ELEV $0.33
- Resistance Level
- ZEO $1.69
- ELEV $0.37
- Average True Range (ATR)
- ZEO 0.14
- ELEV 0.03
- MACD
- ZEO -0.00
- ELEV 0.00
- Stochastic Oscillator
- ZEO 14.71
- ELEV 25.54
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.